Claims for Patent: 5,319,097

Summary for Patent: 5,319,097

Title:	Pharmaceutical agents
Abstract:	The invention provides a pharmaceutical composition comprising a particular physical form of N-[4-[5-(cyclopentyloxy-carbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide and polyvinylpyrrolidone. It also provides methods for preparing this physical form, and another physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxybenzoyll-2-methylbenzenesulphonamide useful in the preparation of the first mentioned physical form. The compositions are useful in the treatment of diseases in which leukotrienes are implicated, for example asthma.
Inventor(s):	James J. Holohan, Ieuan J. Edwards
Assignee:	AstraZeneca UK Ltd , Syngenta Ltd
Application Number:	US07/805,421
Patent Claims:	1. A physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3methoxybenzoyl]-2-methylbenzenesulphonamide which physical form is a monohydrate of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxybenzoyl]-2-methylbenzene-sulphonamide which is crystalline, has an infra-red spectrum (0.5% in KBr) having sharp peaks at 3560, 1690, 1660, 1540, 1440, 1165, 880 and 858cm-1, and an X-ray powder diffraction pattern having peaks at 2θ=10.0°, 11.2°, 14.6°, 19.8°and 23.0°. 2. A physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3methoxybenzoyl]-2-methylbenzenesulphonamide, as claimed in claim 1, which physical form is a monohydrate of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide which is crystalline, has an infra-red spectrum (0.5% in KBr) having sharp peaks at 3560, 1690, 1660, 1540, 1440, 1165, 880 and 858cm-1 ; an X-ray powder diffraction pattern having peaks at 2θ=10.0°, 11.2°, 14.6°, 19.8° and 23.0°; and a melting point in the range from 145° to 155° C. 3. A physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide as claimed in claim 1 which is substantially free of any other physical forms. 4. A physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide as claimed in claim 1 which is substantially free of other crystalline forms. 5. A process for preparing a physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3yl-methyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide which physical form has an infra-red spectrum (0.5% in KBr) having sharp peaks at 1690, 1530, 1490, 1420, 1155, 1060, 862 and 550cm-1 and a melting point between 115° and 140° C., which comprises spray drying a solution of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide. 6. A process as claimed in claim 5, in which an aqueous acetone solution is used. 7. A solution of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide in aqueous acetone.